Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice

Lisa Polin, Frederick Valeriote, Kathryn White, Chiab Panchapor, Susan Pugh, Juiwanna Knight, Patricia LoRusso, Maha Hussain, Elaine Liversidge, Nancy Peltier, Trimurtulu Golakoti, Gregory Patterson, Richard Moore, Thomas H. Corbett*

*Corresponding author for this work

Research output: Contribution to journalArticle

43 Scopus citations

Abstract

Both the PC-3 and the TSU-PR1 prostate tumor models were found to be satisfactory for chemotherapeutic investigations in ICR-SCID mice. The 30 to 60 mg fragments implanted took in all mice (as judged by 100% takes in the controls of all experiments as well as the passage mice). The tumor volume doubling time was 4.0 days for PC-3 and 2.5 days for TSU-PR1. Nine agents were evaluated IV against early stage subcutaneous PC-3 tumors, with Nano-piposulfan being the only agent highly active (4.9 log kill). Three other agents were moderately active: Taxol (1.5 log kill), Cryptophycin-8 (1.6 log kill), Vinblastine (1.0 log kill). Five agents were inactive: VP-16, Adriamycin, CisDDPt, 5-FUra, and Cyclophosphamide. Ten agents were evaluated IV against early stage subcutaneous TSU-PR1 tumors. Three agents were highly active, producing > 6 log kill and cures: Taxol (5/5 cures), Cryptophycin-8 (5/5 cures), Vinblastine (2/4 cures). Two other agents were moderately active: Nano-piposulfan (1.2 log kill), and Cyclophosphamide (1.1 log kill). Five agents were inactive: VP-16, Adriamycin, CisDDPt, 5-FUra, and BCNU. In part, activity was determined by the ability of the SCID mice to tolerate meaningful dosages of the agents. Agents producing granulocyte toxicity (e.g., Adriamycin) were poorly tolerated and appeared less active than expected. Vinblastine, producing little or no granulocyte toxicity was very well tolerated and appeared to be more active than expected.

Original languageEnglish (US)
Pages (from-to)99-108
Number of pages10
JournalInvestigational New Drugs
Volume15
Issue number2
DOIs
StatePublished - Jun 25 1997

Keywords

  • Chemotherapy
  • PC-3
  • Preclinical
  • Prostate tumors
  • TSU-PR1

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice'. Together they form a unique fingerprint.

  • Cite this

    Polin, L., Valeriote, F., White, K., Panchapor, C., Pugh, S., Knight, J., LoRusso, P., Hussain, M., Liversidge, E., Peltier, N., Golakoti, T., Patterson, G., Moore, R., & Corbett, T. H. (1997). Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice. Investigational New Drugs, 15(2), 99-108. https://doi.org/10.1023/A:1005856605726